Blueprint Medicines Corp to Discuss the FDA Approval of GAVRETO Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Blueprint Medicines Conference Call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions). I would now like to hand the conference over to your speaker today, Ms. Kristin Hodous. Thank you. Please go ahead, ma'am.
Thank you, operator. Good morning, everyone, and welcome to Blueprint Medicines conference call to discuss the FDA approval of GAVRETO. You can access the press release announcing the approval as well as the slides that we'll be reviewing today by going to the Investors and Media section of our website at www.blueprintmedicines.com.
With me on the call today are Jeff Albers, our Chief Executive Officer; Dr. Andy Boral, our Chief Medical Officer; and Christina Rossi, our Chief Commercial Officer.
Before we get started, I would like to remind everyone that statements we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
